Psoriasis (PsO) is a chronic autoimmune condition that has long been treated with traditional Janus kinase (JAK) inhibitors, which often come with significant side effects. However, a new oral therapy called Zasocitinib (TAK-279) is emerging as a promising alternative, offering superior selectivity and safety.
The Role of TYK2
TYK2 is a key enzyme involved in the signal transduction of several cytokines, including interleukin-23 (IL-23), IL-12, and type I interferons, all of which play a role in the pathogenesis of immune-mediated inflammatory diseases (IMIDs) like psoriasis. Unlike JAK1/2/3, which are often inhibited simultaneously by traditional JAK inhibitors and can lead to off-target effects such as serious infections, cardiovascular events, and hematologic abnormalities, TYK2 provides a more refined target. This specificity allows for potent therapeutic efficacy with a potentially more favorable safety profile.
Zasocitinib’s Pharmacological Profile
A recent study published in the Journal of Investigative Dermatology provides the most comprehensive pharmacological analysis of Zasocitinib to date. The research shows that Zasocitinib binds to the TYK2 Janus homology 2 (JH2) domain with an inhibitory constant (Ki) of 0.0087 nM, demonstrating over a 1 million-fold selectivity over JAK1 JH2. This is significantly higher than the 87-fold selectivity of deucravacitinib, the only FDA-approved TYK2 inhibitor.
In human whole blood assays, Zasocitinib potently inhibited TYK2-mediated pathways such as IL-23-pSTAT3, type I IFN-pSTAT3, and IL-12-pSTAT4, with half-maximal inhibitory concentrations (IC₅₀s) ranging from 21.6 to 57.0 nM. Notably, even at concentrations as high as 30,000 nM, there was no measurable inhibition of JAK1/2/3.
Clinical Trial Results
Clinical trials have further reinforced the potential of Zasocitinib. In a phase 2b trial,33%of patients on the 30 mg dose achieved complete skin clearance (PASI 100) by week 12. In psoriatic arthritis, patients receiving the highest dose experienced rapid improvements in both skin and joint symptoms, with meaningful responses observed as early as 2 weeks into therapy. Importantly, these benefits were achieved without increased rates of serious infections, cardiovascular events, or thromboembolic complications, which are common concerns with broader JAK inhibition.
Pharmacokinetic Advantages
Zasocitinib’s extended half-life (16.5 to 30.7 hours) compared to deucravacitinib (10 hours) allows for sustained inhibition and the convenience of once-daily dosing. Pharmacokinetic simulations at a clinically relevant dose (30 mg once daily) showed that Zasocitinib maintained plasma concentrations above the TYK2 IC90 threshold for a full 24-hour period, suggesting strong and sustained target engagement.
Future Outlook
Ongoing phase 3 clinical trials (NCT06550076, NCT06088043) will help establish the long-term safety and efficacy of Zasocitinib. The data so far suggest that Zasocitinib could be a highly promising oral treatment option for patients with moderate-to-severe IMIDs, offering a potential alternative to biologic therapies or existing small-molecule inhibitors.
Related Topics:
